Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII Compound in Children with Hemophilia A

WAYNE, N.J., July 8, 2013 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.  The PROTECT VIII...